Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)

A Randomized Double-Blind Placebo-Controlled Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Subjects With Type 2 Diabetes

This study will assess the initial safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-8655, after single and multiple daily oral administrations to participants with Type 2 Diabetes (T2DM). The study will assess the reduction in fasting plasma glucose concentrations from baseline after multiple daily administrations of MK-8655.

Inclusion Criteria:

• Male or female of non-child bearing potential
• Body Mass Index ≤40 kg/m^2
• Diagnosis of Type 2 Diabetes (T2DM) and is either drug naive or is being treated with metformin only
• In good health except for T2DM
• Willing to follow a standard diet
• Nonsmoker and/or no use of nicotine or nicotine-containing products for 6 months

Exclusion Criteria:

• Mentally or legally incapacitated
• History of stroke, chronic seizures, or major neurological disorder
• History of clinically significant endocrine (except T2DM), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
• History of neoplastic or myeloproliferative diseases
• Has clinical unstable or rapidly progressing diabetic retinopathy, neuropathy, and/or frequent nausea, bloating or vomiting, severe gastroesophageal reflux or early satiety
• Has a history of Type 1 Diabetes and/or history of ketoacidosis
• Use of any lipid-lowering therapies in the past 3 months
• Non-permitted medication for a co-morbid condition
• Excessive alcohol or caffeine use
• Participation in another investigational study within 4 weeks prior to this study
• A history of significant multiple and/or severe allergies or anaphylactic reactions
• Regular user of any illicit drugs or history of alcohol abuse within 6 months